Researchers from The Australian National University (ANU) have developed an innovative blood test using nanotechnology and artificial intelligence (AI) that may predict the onset of Alzheimer’s disease up to two decades before symptoms manifest.
The test, published in the journal Small Methods, is touted as simple, cost-effective, and non-invasive.
The technology involves a silicon chip with nanopores, minute holes at the nanometer scale, that can analyze proteins in blood.
A small blood sample is placed on this chip, which is then inserted into a portable device resembling a mobile phone.
Advanced AI algorithms then analyze these proteins, searching for signs of early neurodegeneration that could indicate Alzheimer’s or other neurological conditions like Parkinson’s disease, multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS).
Benefits of Early Detection
While there is no cure for Alzheimer’s disease, early detection could provide people with an opportunity to make lifestyle changes and adopt medication strategies to slow down the disease’s progression.
According to ANU Ph.D. researcher Shankar Dutt, knowing one’s risk level 20 years in advance can significantly improve patient outcomes.
Convenience and Accessibility
One of the most promising aspects of the test is its convenience. “The quick and simple test could be done by GPs and other clinicians, eliminating the need for a hospital visit,” said co-author Professor Patrick Kluth.
This feature is particularly useful for people living in remote or regional areas, offering a more accessible method compared to traditional, more invasive tests like lumbar punctures.
Implications for Diverse Populations
Dementia is a significant public health concern in Australia, particularly among Aboriginal and Torres Strait Islander communities, who are three to five times more likely to develop dementia compared to the general population.
This test could be an essential tool in reducing these health disparities.
Future Outlook
The researchers are optimistic that the screening technique could be made available within the next five years.
“Blood is a complex fluid containing more than 10,000 different biomolecules. With our advanced techniques and machine learning algorithms, we hope to identify even the most elusive proteins,” said Dutt.
Conclusion
This groundbreaking test could revolutionize the way Alzheimer’s and other neurodegenerative diseases are diagnosed, allowing for earlier intervention and potentially better outcomes for patients.
With its combination of simplicity, affordability, and non-invasiveness, the test is poised to be a game-changer in the field of neurodegenerative disease diagnosis.
If you care about Alzheimer’s disease, please read studies that bad lifestyle habits can cause Alzheimer’s disease, and this new drug may help treat Alzheimer’s disease.
For more information about brain health, please see recent studies about a new early sign of Alzheimer’s disease, and results showing this brain problem can increase risk of stroke for up to five years.
The research findings can be found in Small Methods.
Follow us on Twitter for more articles about this topic.
Copyright © 2023 Knowridge Science Report. All rights reserved.
